Skip to main content
Ascletis Pharma Inc. logo

Ascletis Pharma Inc. — Investor Relations & Filings

Ticker · 1672 ISIN · KYG0520K1094 LEI · 254900SKEFCO9I3GPL05 HKEX Manufacturing
Open in API
Filings indexed 1,470 across all filing types
Latest filing 2023-09-05 Transaction in Own Shar…
Country KY Cayman Islands
Listing HKEX 1672

About Ascletis Pharma Inc.

http://www.ascletis.com

Ascletis Pharma Inc. is a fully integrated, R&D driven biotechnology company dedicated to the development and commercialization of potential best-in-class and first-in-class therapeutics. The company covers the entire value chain from discovery to sales. Ascletis primarily focuses on metabolic diseases, including chronic weight management, utilizing proprietary platforms such as Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD), Ultra-Long-Acting Platform (ULAP), and Peptide Oral Transport ENhancement Technology (POTENT). Key pipeline candidates include ASC30 (oral/subcutaneous GLP-1R agonist), ASC35 (GLP-1R/GIPR dual agonist), ASC36 (amylin receptor agonist), and ASC37 (GLP-1R/GIPR/GCGR triple agonist). The company also maintains active programs in viral diseases, NASH/PBC, and oncology.

Recent filings

Filing Released Lang Actions
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued share capital and share buybacks by Ascletis Pharma Inc. It includes detailed information on repurchases of shares, dates, quantities, prices, and confirmations of compliance with listing rules on the Stock Exchange of Hong Kong. The content focuses on share repurchase activities and disclosures required by the exchange rules. There is no indication of a full financial report, earnings release, or management discussion. The document is a regulatory disclosure about share repurchases and capital changes, fitting the category of Transaction in Own Shares (POS). The document length is over 10,000 characters and contains substantive data, not just an announcement or certification, so it is not RPA or RNS.
2023-09-05 English
Monthly Return of Equity Issuer on movements in Securities for the month ended 31 August 2023
Regulatory Filings Classification · 95% confidence The document is a detailed monthly return on movements in securities for World Houseware (Holdings) Limited, including authorized share capital, issued shares, share options, and confirmations related to securities issued. It is addressed to the Hong Kong Exchanges and Clearing Limited and references compliance with the Exchange Listing Rules. The document does not contain financial statements or earnings data but focuses on share capital and securities movements. It is a regulatory submission reporting share capital and securities movements rather than a financial report or announcement of voting results. This type of document fits best under Regulatory Filings (RNS) as it is a compliance report submitted to the exchange without financial performance data or meeting materials.
2023-09-05 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2023
Transaction in Own Shares Classification · 95% confidence The document is titled 'Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules on Movements in Securities' for the month ended 31 August 2023. It details movements in authorized and issued shares, share options, repurchases, and cancellations of shares. The document is submitted to the Hong Kong Exchanges and Clearing Limited and includes detailed tables on share capital changes and share repurchases. This type of filing is a regulatory submission reporting share capital movements and share repurchase activities, which aligns with announcements related to share capital changes or transactions in own shares. Given the detailed reporting of share repurchases and cancellations, the document fits best under the category of Transaction in Own Shares (POS). The document length (7427 characters) and content indicate it is a full report of share movements, not just an announcement or summary, so it is not a Regulatory Filing (RNS) or Report Publication Announcement (RPA).
2023-09-05 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued share capital and share buybacks by Ascletis Pharma Inc. It includes detailed information on repurchases of shares, dates, quantities, prices, and confirmations of compliance with listing rules on the Stock Exchange of Hong Kong. The content focuses on reporting share repurchase transactions and capital changes rather than announcing a new report or providing financial results. The document length is over 10,000 characters, indicating it is a substantive disclosure rather than a brief announcement. This matches the definition of a 'Transaction in Own Shares' filing, which reports company buybacks or sales of its own shares.
2023-09-04 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued share capital and share buybacks by Ascletis Pharma Inc. It includes detailed information on repurchases of shares, dates, quantities, prices, and confirmations of compliance with listing rules on the Stock Exchange of Hong Kong. The content focuses on reporting share repurchase transactions and capital changes rather than financial results, management changes, or other report types. The document length is over 10,000 characters and contains substantive data on share repurchases. This matches the definition of a 'Transaction in Own Shares' filing, which reports company buybacks or sales of its own shares.
2023-08-31 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 95% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued share capital and share buybacks by Ascletis Pharma Inc. It includes detailed information on repurchases of shares, dates, quantities, prices, and confirmations of compliance with listing rules on the Stock Exchange of Hong Kong. The document is a regulatory disclosure about share repurchases and changes in capital, not a full financial report or earnings release. It is a formal announcement of share buyback activity and capital changes, fitting the category of Transaction in Own Shares (POS). The document length is over 10,000 characters, indicating it is a substantive disclosure rather than a brief announcement or certification. Therefore, the appropriate classification is POS with high confidence.
2023-08-30 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.